Lv5
938 积分 2024-06-11 加入
Immunotherapy plus chemoradiotherapy in cervical cancer management
8天前
已完结
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
8天前
已完结
Short-term high-dose gemcitabine induces PERK-mediated immunogenic cell death and potentiates antitumor immunity in bladder cancer
22天前
已关闭
Continuous low‐dose gemcitabine in primary cutaneous T cell lymphoma: A retrospective study
22天前
已完结
Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study
27天前
已完结
Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
28天前
已完结
Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC
28天前
已完结
Structural Perspectives in the Development of Novel EGFR Inhibitors forthe Treatment of NSCLC
28天前
已完结
Treatment outcomes and prognosis of patients with primary and acquired BRAF‐mutated non‐small cell lung cancer: A multicenter retrospective study
1个月前
已完结
PL03.06 EA5181: Phase 3 Trial of Concurrent and Consolidative Durvalumab vs Consolidation Durva Alone for Unresectable Stage 3 NSCLC
1个月前
已关闭
皖公网安备34019202002308
